bismuth subsalicylate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
4257 14882-18-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • bismuth subsalicylate
  • bismogenol
  • bismuth oxysalicylate
bismuth subsalicylate is the active ingredient of Pepto-Bismol and in Kaopectate; used to treat nausea, heartburn, indigestion, upset stomach, diarrhea and other temporary discomforts of the stomach; used with Azoles and other drugs to treat Helicobacter
  • Molecular weight: 362.09
  • Formula: C7H5BiO4
  • CLOGP: 0.34
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 1
  • TPSA: 55.76
  • ALOGS: -0.78
  • ROTB: 0
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,ACVRL1,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GRK3,GSK3B,IGF1R,ITK,JAK1,JAK2,JAK3,KDR,KIT,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAPK10,MAPK12,MAPK7,MAPK9,MAPKAPK2,MARK4,MTOR,NTRK2,PDK1,PDK2,PDPK1,PIK3CB,PIK3CD,PIM2,PLK1,PLK2,PLK3,PLK4,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ZAP70 63
kinase-selectivity-class ACVR2A,ACVR2B,AXL,BRAF,CDK9,DYRK1B,EIF2AK3,GRK2,MAP2K6,MAPK7,PRKDC,SIK2,STK33,TEK,TTK 15
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
Aug. 15, 1996 FDA PROMETHEUS LABS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Chronic kidney disease 106.55 20.80 50 4101 50141 90574155
Diarrhoea 79.24 20.80 148 4003 939042 89685254
Cholecystitis chronic 52.61 20.80 19 4132 9807 90614489
End stage renal disease 36.45 20.80 14 4137 8557 90615739
Nausea 27.74 20.80 112 4039 1110204 89514092
Renal injury 27.39 20.80 12 4139 10231 90614065
Pancreatic enzymes increased 24.13 20.80 6 4145 864 90623432
Cholelithiasis 22.71 20.80 19 4132 52487 90571809
Faeces discoloured 21.65 20.80 13 4138 21307 90602989
Eye symptom 21.19 20.80 4 4147 157 90624139

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Appendicolith 164.12 31.10 60 4617 13396 42603262
Blood phosphorus increased 157.03 31.10 57 4620 12468 42604190
Appendicitis 145.92 31.10 62 4615 20551 42596107
Ventricular fibrillation 129.35 31.10 64 4613 30059 42586599
Myasthenia gravis 115.71 31.10 49 4628 16088 42600570
Hyperphosphataemia 111.93 31.10 45 4632 12959 42603699
Blood uric acid increased 107.46 31.10 46 4631 15501 42601157
Abdominal distension 106.99 31.10 77 4600 71658 42545000
Dry mouth 104.44 31.10 61 4616 39818 42576840
Ascites 103.69 31.10 69 4608 56609 42560049
Cardiogenic shock 99.93 31.10 57 4620 35583 42581075
Blood cholesterol increased 92.11 31.10 49 4628 26692 42589966
Stress 91.06 31.10 58 4619 44154 42572504
Analgesic therapy 90.42 31.10 32 4645 6492 42610166
Hypophosphataemia 88.37 31.10 44 4633 20901 42595757
Neuralgia 88.35 31.10 47 4630 25600 42591058
Iron deficiency 87.38 31.10 36 4641 11025 42605633
Sleep disorder therapy 81.26 31.10 30 4647 6864 42609794
Drug therapy 76.07 31.10 28 4649 6352 42610306
Intentional product misuse 73.46 31.10 58 4619 61842 42554816
Bacterial infection 71.24 31.10 42 4635 27837 42588821
Hyponatraemia 70.20 31.10 70 4607 101392 42515266
Chronic kidney disease 66.46 31.10 49 4628 47192 42569466
Incorrect route of product administration 65.75 31.10 38 4639 24267 42592391
Multiple organ dysfunction syndrome 65.38 31.10 66 4611 96969 42519689
End stage renal disease 64.60 31.10 33 4644 16525 42600133
Swelling 59.94 31.10 49 4628 54836 42561822
Diabetes mellitus 56.07 31.10 49 4628 60038 42556620
Chronic obstructive pulmonary disease 53.99 31.10 49 4628 63065 42553593
Thrombosis 50.55 31.10 49 4628 68462 42548196
Vomiting 44.59 31.10 98 4579 289625 42327033
Somnolence 42.56 31.10 64 4613 141041 42475617
Sleep disorder 42.41 31.10 38 4639 48057 42568601
Abdominal pain 42.04 31.10 75 4602 190396 42426262
Drug intolerance 40.59 31.10 47 4630 80377 42536281
Bacteroides infection 37.02 31.10 13 4664 2574 42614084
Total lung capacity decreased 36.48 31.10 14 4663 3556 42613102
Activated partial thromboplastin time prolonged 35.54 31.10 22 4655 15881 42600777
Ulcer 34.87 31.10 22 4655 16419 42600239
Pulmonary embolism 34.27 31.10 53 4624 119559 42497099
Aortic stenosis 32.85 31.10 17 4660 8728 42607930
General physical health deterioration 32.62 31.10 59 4618 151187 42465471
Capillary permeability increased 31.47 31.10 5 4672 26 42616632
Nausea 31.38 31.10 105 4572 396694 42219964
Drug hypersensitivity 31.25 31.10 46 4631 99343 42517315

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Appendicolith 190.45 19.87 61 7768 14194 110567276
Blood phosphorus increased 170.42 19.87 58 7771 16282 110565188
Appendicitis 156.13 19.87 63 7766 28401 110553069
Ventricular fibrillation 139.75 19.87 65 7764 41248 110540222
Myasthenia gravis 122.76 19.87 49 7780 21462 110560008
Blood uric acid increased 122.72 19.87 49 7780 21480 110559990
Hyperphosphataemia 120.92 19.87 45 7784 16336 110565134
Ascites 109.63 19.87 73 7756 92735 110488735
Analgesic therapy 104.82 19.87 33 7796 7251 110574219
Cardiogenic shock 103.17 19.87 59 7770 57279 110524191
Chronic kidney disease 102.34 19.87 65 7764 76226 110505244
Sleep disorder therapy 95.79 19.87 31 7798 7440 110574030
Abdominal distension 91.38 19.87 85 7744 175018 110406452
Drug therapy 88.40 19.87 29 7800 7262 110574208
Iron deficiency 88.06 19.87 37 7792 18439 110563031
Hypophosphataemia 87.39 19.87 44 7785 33138 110548332
Neuralgia 84.84 19.87 49 7780 48429 110533041
End stage renal disease 79.53 19.87 36 7793 21437 110560033
Stress 74.84 19.87 61 7768 105287 110476183
Intentional product misuse 72.18 19.87 66 7763 132838 110448632
Multiple organ dysfunction syndrome 72.18 19.87 70 7759 151640 110429830
Bacterial infection 68.72 19.87 42 7787 45994 110535476
Thrombosis 57.12 19.87 53 7776 108609 110472861
Hyponatraemia 54.62 19.87 72 7757 217581 110363889
Diabetes mellitus 53.25 19.87 49 7780 99332 110482138
Dry mouth 53.06 19.87 68 7761 199880 110381590
Abdominal pain 50.82 19.87 112 7717 512877 110068593
Chronic obstructive pulmonary disease 47.50 19.87 48 7781 109110 110472360
Incorrect route of product administration 47.39 19.87 38 7791 64023 110517447
Vomiting 46.86 19.87 156 7673 910519 109670951
Nausea 43.96 19.87 188 7641 1235502 109345968
Bacteroides infection 41.06 19.87 13 7816 2906 110578564
Somnolence 40.24 19.87 74 7755 297375 110284095
Activated partial thromboplastin time prolonged 40.16 19.87 23 7806 22345 110559125
Pulmonary embolism 39.15 19.87 61 7768 214413 110367057
Cholecystitis chronic 38.60 19.87 17 7812 9483 110571987
Aortic stenosis 33.44 19.87 17 7812 13042 110568428
Antacid therapy 33.04 19.87 13 7816 5471 110575999
Blood cholesterol increased 32.94 19.87 52 7777 184733 110396737
Anticoagulant therapy 29.83 19.87 12 7817 5349 110576121
Total lung capacity decreased 29.78 19.87 13 7816 7101 110574369
Capillary permeability increased 29.45 19.87 5 7824 67 110581403
Sleep disorder 28.85 19.87 51 7778 198593 110382877
Diarrhoea 28.59 19.87 157 7672 1139348 109442122
Gout 27.69 19.87 22 7807 36544 110544926
Sepsis 26.37 19.87 66 7763 327280 110254190
Ulcer 24.53 19.87 22 7807 43094 110538376
Hyperlipidaemia 23.85 19.87 20 7809 35828 110545642
Blood calcium increased 23.24 19.87 15 7814 18025 110563445
Nephrogenic anaemia 21.25 19.87 9 7820 4568 110576902
Troponin increased 20.62 19.87 17 7812 29749 110551721
Polyserositis 20.51 19.87 6 7823 1028 110580442

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
FDA CS M0002611 Bismuth
MeSH PA D000930 Antidiarrheals
MeSH PA D005765 Gastrointestinal Agents
FDA EPC N0000180183 Bismuth
CHEBI has role CHEBI:33282 antibacterial agent
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:50919 antiemetic

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Diarrhea indication 62315008
Indigestion indication 162031009
Duodenal Ulcer due to H. Pylori indication
Traveler's diarrhea off-label use 11840006
Helicobacter pylori-associated gastritis off-label use 708164002
Helicobacter Pylori Gastritis off-label use
Alcoholism contraindication 7200002
Lowered convulsive threshold contraindication 19260006
Alcohol intoxication contraindication 25702006
Hepatic failure contraindication 59927004
Blood coagulation disorder contraindication 64779008 DOID:1247
Diabetes mellitus contraindication 73211009 DOID:9351
Disorder of brain contraindication 81308009 DOID:936
Gout contraindication 90560007 DOID:13189
Kidney disease contraindication 90708001 DOID:557
Seizure disorder contraindication 128613002
Non-infective meningitis contraindication 230155003
Disease of liver contraindication 235856003 DOID:409
Pregnancy, function contraindication 289908002
Peripheral nerve disease contraindication 302226006
Neutropenic disorder contraindication 303011007 DOID:1227
Pseudomembranous enterocolitis contraindication 397683000
Breastfeeding (mother) contraindication 413712001




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Cyclooxygenase Enzyme INHIBITOR CHEMBL CHEMBL

External reference:

IDSource
4018971 VUID
N0000147252 NUI
D00728 KEGG_DRUG
4018971 VANDF
C0053792 UMLSCUI
CHEBI:261649 CHEBI
CHEMBL1120 ChEMBL_ID
DB01294 DRUGBANK_ID
C015715 MESH_SUPPLEMENTAL_RECORD_UI
62TEY51RR1 UNII
53629521 PUBCHEM_CID
19478 RXNORM
4290 MMSL
d01026 MMSL
001159 NDDF
409307004 SNOMEDCT_US
82075003 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Percy Medicine HUMAN OTC DRUG LABEL 1 0322-2222 LIQUID 1050 mg ORAL OTC Monograph Drug 8 sections
Percy Medicine HUMAN OTC DRUG LABEL 1 0322-2222 LIQUID 1050 mg ORAL OTC Monograph Drug 8 sections
Soothe HUMAN OTC DRUG LABEL 1 0363-0073 LIQUID 525 mg ORAL OTC Monograph Drug 16 sections
Soothe HUMAN OTC DRUG LABEL 1 0363-0073 LIQUID 525 mg ORAL OTC Monograph Drug 16 sections
Soothe HUMAN OTC DRUG LABEL 1 0363-0736 LIQUID 525 mg ORAL OTC Monograph Drug 16 sections
Soothe HUMAN OTC DRUG LABEL 1 0363-0736 LIQUID 525 mg ORAL OTC Monograph Drug 16 sections
Ultra Strength digestive relief HUMAN OTC DRUG LABEL 1 0363-1302 TABLET 525 mg ORAL OTC Monograph Drug 17 sections
Walgreen Stomach Relief HUMAN OTC DRUG LABEL 1 0363-1423 TABLET, CHEWABLE 262 mg ORAL OTC Monograph Drug 16 sections
Stomach Relief HUMAN OTC DRUG LABEL 1 0363-7024 LIQUID 525 mg ORAL OTC Monograph Drug 16 sections
Stomach Relief HUMAN OTC DRUG LABEL 1 0363-7024 LIQUID 525 mg ORAL OTC Monograph Drug 16 sections
WALGREENULTRA STRENGTH PINK BISMUTH HUMAN OTC DRUG LABEL 1 0363-7070 SUSPENSION 525 mg ORAL OTC Monograph Drug 16 sections
WALGREENULTRA STRENGTH PINK BISMUTH HUMAN OTC DRUG LABEL 1 0363-7070 SUSPENSION 525 mg ORAL OTC Monograph Drug 16 sections
Walgreen Stomach Relief Ultra Strength HUMAN OTC DRUG LABEL 1 0363-7071 SUSPENSION 525 mg ORAL OTC Monograph Drug 16 sections
Walgreen Stomach Relief Ultra Strength HUMAN OTC DRUG LABEL 1 0363-7071 SUSPENSION 525 mg ORAL OTC Monograph Drug 16 sections
Soothe HUMAN OTC DRUG LABEL 1 0363-7240 LIQUID 525 mg ORAL OTC Monograph Drug 16 sections
Soothe HUMAN OTC DRUG LABEL 1 0363-7240 LIQUID 525 mg ORAL OTC Monograph Drug 16 sections
SootheUltra Strength HUMAN OTC DRUG LABEL 1 0363-7370 LIQUID 525 mg ORAL OTC Monograph Drug 16 sections
SootheUltra Strength HUMAN OTC DRUG LABEL 1 0363-7370 LIQUID 525 mg ORAL OTC Monograph Drug 16 sections
Walgreen HUMAN OTC DRUG LABEL 1 0363-9124 TABLET, CHEWABLE 262 mg ORAL OTC Monograph Drug 16 sections
Walgreen HUMAN OTC DRUG LABEL 1 0363-9124 TABLET, CHEWABLE 262 mg ORAL OTC Monograph Drug 16 sections
Walgreen HUMAN OTC DRUG LABEL 1 0363-9125 TABLET, FILM COATED 262 mg ORAL OTC Monograph Drug 16 sections
Walgreen HUMAN OTC DRUG LABEL 1 0363-9125 TABLET, FILM COATED 262 mg ORAL OTC Monograph Drug 16 sections
Walgreens Bismuth Stomach Relief HUMAN OTC DRUG LABEL 1 0363-9954 TABLET, CHEWABLE 262 mg ORAL OTC Monograph Drug 17 sections
Stomach ReliefRegular Strength HUMAN OTC DRUG LABEL 1 0536-1286 LIQUID 525 mg ORAL OTC Monograph Drug 16 sections
Stomach ReliefRegular Strength HUMAN OTC DRUG LABEL 1 0536-1286 LIQUID 525 mg ORAL OTC Monograph Drug 16 sections
Stomach ReliefUltra HUMAN OTC DRUG LABEL 1 0536-1287 LIQUID 525 mg ORAL OTC Monograph Drug 16 sections
Stomach ReliefUltra HUMAN OTC DRUG LABEL 1 0536-1287 LIQUID 525 mg ORAL OTC Monograph Drug 16 sections
Major Bismuth Subsalicylate Human OTC Drug Label 1 0904-7205 TABLET, CHEWABLE 262 mg ORAL OTC Monograph Drug 15 sections
up and up 5-symptom digestive relief HUMAN OTC DRUG LABEL 1 11673-122 TABLET 262 mg ORAL OTC Monograph Drug 16 sections
up and up 5-symptom digestive relief HUMAN OTC DRUG LABEL 1 11673-122 TABLET 262 mg ORAL OTC Monograph Drug 16 sections